Sensorion: A Chardan Top Pick for 2021
Regulatory News:
Sensorion (FR0012596468 ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the US healthcare investment bank Chardan decision to make Sensorion one of its top picks for 2021, calling the company 2021 s hidden gem in gene therapy .
It raised its target price to €7, following the announcement of a third gene therapy collaboration with Pasteur Institut targeting important pediatric and adult deafness segments (
target gene GJB2).
Chardan initiated coverage of Sensorion in June 2020 with a recommended purchase price of €2.00, which was raised to €5.00 in August, based on the company s potential to become a leader in the development of gene therapies for the treatment of hearing loss.
Sensorion : A Chardan Top Pick for 2021
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
(2)
Regulatory News:
Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the company s Board of Directors has approved the procedure for holding an Extraordinary General Meeting behind closed doors (
à huis clos) on Wednesday, March 24, 2021.
In accordance with article 4 of ordinance n° 2020-321 of March 25, 2020 as amended by ordinance n° 2020-1497 of December 2, 2020 adapting the rules for meetings and deliberations of general meetings and governing bodies of legal entities and entities without legal personality under private law due to the Covid-19 epidemic, the Board of Directors decided to hold the Extraordinary General Meeting of March 24, 2021 behind closed doors, without the shareholders, and other persons entitled to attend, being present, either physically or by telephone or audiovisual confere
(2)
Key new findings by the Institut Pasteur concerning the gene target GJB2, enables Sensorion to potentially address important hearing loss segments in adults and children
GJB2 mutations are the most prevalent cause of congenital deafness; the gene target potentially opens up a pipeline of indications
Three initial indications to be targeted: congenital deafness, a progressive form of hearing loss in childhood and early onset of severe presbycusis in adults
Webcast planned for Tuesday, February 16 at 2:00pm CET
Regulatory News:
Sensorion (Paris:ALSEN)(FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the addition of a new gene therapy target,
Half-year report on the Sensorion liquidity contract with Kepler Cheuvreux
Regulatory News:
Sensorion (FR0012596468 ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, issued the half-year report on its liquidity contract with Kepler Chevreux.
As of December 31, 2020, the following assets appeared on the liquidity account
Sensorion ordinary shares
33 243,51
It is reminded that as of June 30, 2020, the following assets appeared on the liquidity account
Sensorion ordinary shares
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has buil
vimarsana © 2020. All Rights Reserved.